Loading
A phase 2 trial of Tusamitamab ravtansine and Gemcitabine in Breast cancer, run by Sanofi, recorded as terminated on the registry.
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors is a phase 2 interventional study registered as NCT04659603 by Sanofi, with 50 participants recorded, started 2021-03-29 and due to reach its primary completion in 2024-02-16. Interventions recorded: tusamitamab ravtansine, Gemcitabine. Conditions recorded: Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic.
Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
50 enrolled.
95% CI 0.00 to 45.93; Figures from the ClinicalTrials.gov results section (first posted 2025-03-25), not from a publication · 95% CI 0.09 to 18.35 · 95% CI 11.02 to 58.66
Source95% CI 1.314 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-03-25), not from a publication · 95% CI 1.643 to 2.267 · 95% CI 1.873 to NA
SourceShares Tusamitamab ravtansine, Sanofi and the tag pipeline.
Shares Tusamitamab ravtansine, Sanofi and the tag pipeline.
Shares Sanofi, Gemcitabine, Breast cancer (all types) and the tag pipeline.
Shares Sanofi, Gemcitabine, Breast cancer (all types) and the tag pipeline.
Shares Sanofi, Breast cancer (all types) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.